Pneumococcal

Investigators found inconsistencies across subgroups, but the overall efficacy and safety of pneumococcal vaccination was affirmed.

Pharmacists should ensure pneumococcal vaccination strategies are tailored to high-risk individuals, especially those with type 2 diabetes (T2D).

Using the United States Vaccine Adverse Event Reporting System database, investigators found that pneumococcal vaccination led to predominantly nonserious adverse events.

Pneumococcal 21-valent conjugate vaccine (PCV21) was found to be immunogenic and safe in individuals living with HIV, providing significant indications of efficacy in immunocompromised patients.

A multicenter registry analysis reveals that high-risk cardiovascular patients often miss opportunities to receive pneumococcal and influenza vaccinations, showcasing gaps that could be filled by pharmacists.

Use of educational resources at a gastrointestinal office improved pneumococcal vaccine uptake in patients with celiac disease.

In STRIDE-13, the pneumococcal 21-valent conjugate vaccine (PCV21) induced robust immunogenicity in young, high-risk individuals against invasive pneumococcal disease.

The 21-valent pneumococcal conjugate vaccine (PCV21) elicited favorable immunogenicity and safety in infants and toddlers who were coadministered common pediatric vaccines, such as the measles-mumps-rubella vaccine.

Greater effectiveness was seen in children 1 year and older.

Patients with severe COVID-19 who tested positive for Streptococcus pneumoniae had higher mortality rates.

Alyssa Modic, PharmD, explains how pharmacists can clarify pneumococcal vaccine schedules, manage coadministration decisions, and reframe vaccination conversations for patients.

Patients in an outpatient oncology unit expressed willingness to receive a pneumococcal or influenza vaccine from a pharmacist if offered.

The implementation of nonpharmaceutical measures during the COVID-19 pandemic reduced transmission of Streptococcus pneumoniae, a key bacterium that causes pneumococcal disease.

Case highlights the importance of careful cocumentation.

In a phase 3 trial, V116 demonstrated significant immunogenicity in older adults who had not before received a pneumococcal vaccination.

Older adults in the United States continue to be burdened with disproportionate rates of community-acquired pneumonia hospitalizations, including due to serotypes covered in the recently approved V116 vaccine.

New research highlights a surge in pediatric pneumococcal pneumonia cases post COVID-19, urging a shift toward supportive treatment strategies.

Both vaccine and nonvaccine serotypes were identified as being resistant to critical antimicrobial treatments for pneumococcal disease.

Data from a retrospective study of adults in France found the highest incidence of pneumococcal disease in patients with the highest risk underlying medical conditions.

Conversely, Medicaid enrollees experienced widening gaps of pneumococcal vaccination uptake, likely driven by socioeconomic obstacles.

Education initiatives, facilitation, and immunization on the part of pharmacists were found to significantly increase uptake of pneumococcal vaccines among older adults.

An expert discusses how pharmacists can ensure completion of multidose pneumococcal vaccine series through electronic reminder systems, state immunization registries, scheduled follow-up appointments, and providing patients with printed vaccine cards for tracking purposes.

Since the most recent guidelines were published, more evidence has emerged regarding intravenous corticosteroids for severely ill patients.

Patients with inflammatory rheumatic diseases may have a protective effect against serious COVID-19 outcomes once they receive a pneumococcal vaccination.

An expert discusses how pharmacists can overcome common vaccination barriers by addressing misconceptions about vaccine necessity, making strong provider recommendations, and educating patients about mild adverse effects while building trust through consistent communication.